Cargando…
Rapid response of spesolimab in biologics – failure patient with generalized pustular psoriasis flare
Autores principales: | Jiang, Meng, Li, Yan, Guan, Xin, Li, Linfeng, Xu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485750/ https://www.ncbi.nlm.nih.gov/pubmed/37692270 http://dx.doi.org/10.5114/ada.2023.129514 |
Ejemplares similares
-
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2022) -
Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double‐blind, placebo‐controlled Effisayil™ 1 study
por: Morita, Akimichi, et al.
Publicado: (2022) -
Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018) -
Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
por: Choon, Siew Eng, et al.
Publicado: (2023) -
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
por: Choon, Siew Eng, et al.
Publicado: (2021)